![cbas-hero-nav-img-l-v5](/sites/default/files/styles/max_750x750/public/2021-02/cbas-hero-nav-img-l-v5%2C0.jpg.webp?itok=5nOfdEe7)
CBAS® Heparin Surface
Proven heparin bonding technology for lasting thromboresistance
Dedicated to Innovation: Thromboresistance in Vascular Devices
Gore’s CBAS® Heparin Surface, the proven heparin bonding technology for lasting thromboresistance, is used in many of our interventional and vascular surgery products. End-point covalent bonding keeps heparin anchored to the device, while the bioactive site remains free to interact with the blood to help prevent clotting.*
- Proven heparin availability: Performance-ready heparin active site*,1,4
- Proven heparin bioactivity: Unmatched, persistent ability to take up antithrombin*,2,3
- Proven lasting thromboresistance: Improved surface hemocompatibility resulting from heparin availability and bioactivity*,1-5
Proprietary covalent end-point bonding
![Proprietary covalent end-point bonding](/sites/default/files/styles/max_750x750/public/2022-02/AZ0667-EN1-CBAS-Image-08-FNL-OL.png.webp?itok=7lUEkRry)
Covalent end-point bonding allows the heparin to extend into the bloodstream, keeping the active site bioavailable, unlike a non-permanent bond that can be washed away in the bloodstream.
- The anticoagulant function of heparin is dependent on the bioavailability of an active site within the molecule.
- Some methods of covalent heparin bonding damage and / or obstruct the active site, and hence destroy heparin’s anticoagulant activity.
- The CBAS® Heparin Surface consists of a proprietary covalent end-point bond that preserves the active site, thus retaining heparin’s anticoagulant activity.
Mechanism of action
![Mechanism of action](/sites/default/files/styles/max_750x750/public/2022-02/AZ0667-EN1-CBAS-Image-07-FNL-OL.png.webp?itok=MTWWFwXY)
A. Bioactive site of the heparin molecule enables antithrombin to bind thrombin.
B. When antithrombin binds to thrombin, a neutral thrombin antithrombin (TAT) complex is formed.
C. Neutral TAT complex detaches from the heparin molecule. Active site becomes available to again bind antithrombin.
* See full CBAS® Heparin Surface references.
CBAS® is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc.
Featured Gore Products with CBAS® Heparin Surface
GORE® ACUSEAL Vascular Graft
GORE® PROPATEN® Vascular Graft
GORE® PROPATEN® Vascular Graft configured for Pediatric Shunt
GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis
22589259-EN